Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel

A U.S. Food and Drug Administration committee is likely to give an unfavorable review next month for a key Biogen (BIIB) Alzheimer's treatment, an analyst said in a research report to clients on Monday, an action that could weigh on BIIB stock. It comes as BIIB earnings are due this week.